Abstracts tagged "Infection"

Abstract Number: 2428 • 2017 ACR/ARHP Annual Meeting
Epstein-Barr Virus Infection and Epstein-Barr Virus　Nuclear Antigen 1 Variants in the Synovial Tissue of Rheumatoid Arthritis
Shotaro Masuoka¹, Natsuko Kusunoki¹, Shinichi Kawai² and Toshihiro Nanki¹, ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ²Department of Inflammation and Pain Control Research, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Epstein-Barr virus (EBV) infection causes various malignant tumors such as B cell lymphoma and epithelial cell cancer. Previous reports showed several variants in carboxyl-terminal…
Abstract Number: 541 • 2017 ACR/ARHP Annual Meeting
Decreasing Trend of Serious Infections Incidence Rate Along Years in Rheumatoid Arthritis Patients Exposed to Biologics. Data from Two Latin America Registries
Roberto Ranza¹, Ieda Maria Magalhães Laurindo², Georges Christopoulos², Gimena Gomez³, Enrique R Soriano⁴, Miguel Angel Descalzo⁵ and Maria de la Vega⁶, ¹on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, Uberlandia, Brazil, ²on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, São Paulo, Brazil, ³on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos Aires, Argentina, ⁴Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Research Unit, Fundacion piel sana AEDV, Madrid, Spain, Madrid, Spain, ⁶on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos aires, Argentina
Background/Purpose: Infections are the most frequent and concerning serious adverse events related to rheumatoid arthritis (RA) treatment with biologic drugs (bDMARDs). Their safety profile might…
Abstract Number: 2606 • 2017 ACR/ARHP Annual Meeting
Pneumococcal Vaccination in Patients with Systemic Lupus Erythematosus: A Multicenter Placebo-Controlled Randomized Double-Blind Study
Sophie Grabar¹, Matthieu Groh², Mathilde Bahuaud³, Nathalie Costedoat-Chalumeau⁴, Veronique Le Guern⁵, Renato Fior⁶, Boris Bienvenu⁷, eric hachulla⁸, Mohamed Hamidou⁹, Jean Sibilia¹⁰, Alexis Mathian¹¹, Thomas Hanslik¹², Loïc Guillevin for the French Vasculitis Study Group¹³, Frédéric Batteux³ and Odile Launay¹⁴, ¹Université Paris Descartes, Sorbonne Paris Cité AP-HP, Unité de Biostatistique et Epidémiologie, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Paris, France; INSERM, UPMC Université Paris 06, Institut Pierre Louis d’épidémiologie et de Santé Publique (IP, Paris, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Université Paris Descartes, Sorbonne Paris Cité AP-HP, Département d’Immunologie Biologique, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Paris, France, Paris, France, ⁴Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁵Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, Paris, France, ⁶Université Paris-Sud, AP-HP, Service de Médecine Interne et Immunologie Clinique, Hôpital Antoine Béclère, Clamart, France, Clamant, France, ⁷Internal Medicine, Hôpital de la côte de Nacre, Caen, France, ⁸chru lille hospital, lille, France, ⁹Medecine Interne, CHU Hôtel Dieu, Nantes, France, ¹⁰Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹Université Pierre et Marie Curie, Sorbonne Paris Cité AP-HP, Service de Médecine Interne 2, Centre de Référence National pour le Lupus et le Syndrome des Antiphospholipides, institut E3M, Paris, France, Paris, France, ¹²Université Versailles Saint-Quentin-en-Yvelines, APHP, Service de Médecine Interne, Hôpital Ambroise Paré, Boulogne-Billancourt, France, Boulogne-Billancourt, France, ¹³Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ¹⁴Université Paris Descartes, Sorbonne Paris Cité AP-HP, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Fédération d'Infectiologie, Paris, France; Inserm, F-CRIN I-REIVAC., Paris, France
Background/Purpose: Invasive pneumococcal disease and respiratory tract infections are both frequent and severe in patients with systemic lupus erythematosus (SLE). This study aimed to compare…
Abstract Number: 547 • 2017 ACR/ARHP Annual Meeting
Long-Term Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated with Rituximab: 5 Year Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Diederik De Cock¹, Lianne Kearsley-Fleet¹, Lucía Silva Fernández², Mark Lunt¹, Kath Watson¹, Deborah P.M. Symmons^1,3 and Kimme L. Hyrich^1,3, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ³National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: In the United Kingdom (UK), rituximab (RTX) or a second tumour necrosis factor inhibitor (TNFi) are both permitted treatment options for patients with rheumatoid…
Abstract Number: 2738 • 2017 ACR/ARHP Annual Meeting
Infectious Complications in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials
Lafarge Antoine¹, Christian Pagnoux², Xavier Puéchal³, Maxime Samson⁴, Mohamed Hamidou⁵, Alexandre Karras⁶, Thomas Quémeneur⁷, Matthieu Groh⁸, Luc Mouthon⁹, Loïc Guillevin for the French Vasculitis Study Group³ and Benjamin Terrier¹⁰, ¹Medecine Interne, Hôpital Cochin, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Medecine Interne, CHU Hôtel Dieu, Nantes, France, ⁶nephrology, HEGP, Paris, France, ⁷Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁹Université Paris Descartes Sorbonne Paris, Paris, France, ¹⁰Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: Prognosis of patients with systemic necrotizing vasculitides has been markedly improved during the last 2 decades. However, infectious complications remain a major cause of…
Abstract Number: 697 • 2017 ACR/ARHP Annual Meeting
Does Erythrocyte Sedimentation Rate Reflect and Discriminate Flare from Infection in Systemic Lupus Erythematosus? Correlation with Clinical and Laboratory Parameters of Disease Activity
Valentin S. Schäfer¹, Katharina Weiss², Andreas Krause² and Wolfgang A. Schmidt³, ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Medical Centre for Rheumatology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: ESR is applied for monitoring disease activity in SLE. It is known to be influenced by age and infections. We aimed at evaluating how…
Abstract Number: 2785 • 2017 ACR/ARHP Annual Meeting
Serious Infections Associated with Tofacitinib in Rheumatoid Arthritis Patients Previously Treated with Methotrexate
Marina Amaral de Avila Machado¹, Cristiano S. Moura², Steve Ferreira Guerra¹, Jeffrey R. Curtis³, Michal Abrahamowicz⁴, Hassan Behlouli¹ and Sasha Bernatsky⁵, ¹Department of Medicine, McGill University Health Centre, Montreal, QC, Canada, ²1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, McGill University Health Centre, Montreak, QC, Canada, ⁵Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Little is known about the real-world safety of tofacitinib, an oral Janus kinase inhibitor. We compared serious infections associated with tofacitinib, disease-modifying antirheumatic drugs…
Abstract Number: 808 • 2017 ACR/ARHP Annual Meeting
Assessing the Possible Link between Varicella Zoster Virus and Giant Cell Arteritis Using Clinical Assessment, Serology and Biopsy Antigen Detection – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Cohort
Anthony Sammel¹, Katherine Nguyen², Susan Smith³, Christopher Little³, Janice Brewer² and Rodger Laurent², ¹Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ²Royal North Shore Hospital, St Leonards, Sydney, Australia, ³Raymond Purves Bone and Joint Research Laboratories, Kolling Institute, Sydney, Australia
Background/Purpose: Recent studies have suggested that giant cell arteritis (GCA) may be triggered by reactivation of varicella zoster virus (VZV) based on high rates of…
Abstract Number: 2840 • 2017 ACR/ARHP Annual Meeting
Clinical Presentation and Outcomes in Patients with Prosthetic Joint Septic Arthritis Who Had One-Stage Versus Two-Stage Joint Replacement
Mary Louise Fowler¹, Kevin Byrne², Sarah Lieber³, Robert Shmerling⁴ and Ziv Paz³, ¹2Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Beth Israel Deaconess Medical Center, Boston, MA, ⁴Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Prosthetic joint septic arthritis (PJSA) complicates about 1 to 2 percent of joint replacement surgeries. The management of PJSA usually includes a combination of…
Abstract Number: 1071 • 2017 ACR/ARHP Annual Meeting
Increased Susceptibility of SLE-Prone Mice to Pulmonary Haemophilus Influenzae Infection Was Attributed to Dysfunctions of Innate Immune Responses
Wenchao Li and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Aside from the disease itself, infections represent the major cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients. Although the daily usage…
Abstract Number: 2841 • 2017 ACR/ARHP Annual Meeting
Infection Is the Major Trigger of Adult Hemophagocytic Syndrome, an Orphan Systemic Hyperinflammatory, Life-Threatening Disease: Analysis in 147 Patients (GEAS-SEMI Registry)
Pilar Brito-Zerón¹, Alejandra Flores-Chavez^2,3,4, Pedro Moral Moral⁵, A. Martínez-Zapico⁶, Pilar Hernández-Jimenez⁷, Guadalupe Fraile Rodriguez⁸, Patricia Perez Guerrero⁹, Eva Fonseca¹⁰, Angel Robles¹¹, María Vaquero Herrero¹², Angela Ruiz de Temiño de la Peña¹³, Maria José Forner¹⁴, José Ramón Larrañaga¹⁵, Mónica Rodriguez Carballeira¹⁶, Luis Fernando Viejo Llorente¹⁷, Manuel Ruiz Muñoz¹⁸, Roberto Hurtado¹⁹, César Morcillo²⁰, Soledad Retamozo²¹ and Manuel Ramos-Casals^22,23, ¹Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ²Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ³Programa de Doctorado en Ciencias Médicas, Centro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima, Mexico, Mexico, Mexico, ⁴Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁵Hospital La Fé Valencia, Valencia, Spain, ⁶Hospital Universitario de Asturias, Oviedo, Oviedo, Spain, ⁷Internal Medicine, Hospital 12 de Octubre, Madrid, Spain, ⁸Internal Medicine, Hospital Ramón y Cajal, Madrid, Madrid, Spain, ⁹Department of Internal Medicine, Hospital Universitario Puerta del Mar, Cádiz, Cadiz, Spain, ¹⁰Internal Medicine, Hospital de Cabueñes, Gijón, Gijón, Spain, ¹¹Internal Medicine, Hospital La Paz, Madrid, Madrid, Spain, ¹²Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ¹³Hospital Rio Hortega Valladolid, Valladolid, Spain, ¹⁴Department of Internal Medicine, Hospital Clínico de Valencia, Valencia, Spain, ¹⁵Department of Internal Medicine, Hospital Xeral, Vigo, Vigo, Spain, ¹⁶Hospital Mutua de Terrasa, Terrasa, Spain, ¹⁷Hospital Virgen de la Salud Toledo, Toledo, Spain, ¹⁸Department of Internal Medicine, Hospital Universitario Fundacion Alcorcón, Madrid, Spain, ¹⁹Hospital Vega Baja de Orihuela, Alicante, Spain, ²⁰Department of Medicine, Hospital CIMA-Sanitas, Barcelona, Barcelona, Spain, ²¹Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ²²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²³Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain
Background/Purpose: Hemophagocytic syndrome or hemophagocytic lymphohistiocytosis (HLH) is an increasingly-recognized condition in adults, characterized by a wide range of etiologies, symptoms and outcomes, but with…
Abstract Number: 1440 • 2017 ACR/ARHP Annual Meeting
The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated with Tofacitinib
Kevin Winthrop¹, Ann Wouters², Ernest Choy³, Chudy Nduaka⁴, Pinaki Biswas², Lisy Wang⁵, Jennifer Hodge², Irina Lazariciu⁶, Koshika Soma⁵, Christopher F Mojcik², Elie Needle⁷ and William F C Rigby⁸, ¹Oregon Health & Science University, Portland, OR, ²Pfizer Inc, New York, NY, ³CREATE Center, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT, ⁶QuintilesIMS, Saint-Laurent, QC, Canada, ⁷Pfizer Inc, Pearl River, NY, ⁸Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: RA patients (pts) are at increased risk of herpes zoster (HZ), and ACR guidelines recommend vaccination in pts aged ≥50 years prior to starting…
Abstract Number: 2842 • 2017 ACR/ARHP Annual Meeting
Usefulness of Polymerase Chain Reaction for Diagnosing Whipple’S Disease in Rheumatology
Marion Herbette¹, Jean Baptiste Cren², Laurie Joffres³, charlotte lucas⁴, Emilie Ricard⁵, Carine Salliot⁶, Jerome Guinard⁷, Aleth Perdriger⁸, Elisabeth Solau-Gervais⁹, Béatrice Bouvard¹⁰ and Alain Saraux¹¹, ¹Rheumatology, University Hospital, Brest, France, ²Rheumatology, University Hospital of Angers, Angers, France, ³University Hospital de Poitiers, Poitiers, France, ⁴Rheumatology, University Hospital, Rennes, France, ⁵Rheumatology, University Hospital, Orléans, France, ⁶department of Rheumatology, Orleans, France, ⁷Microbiology, CHU Angers, Angers, France, ⁸Service de Rhumatologie, CHRU de Rennes, Rennes, France, ⁹Rhumatologie, University Hospital, Poitiers, France, ¹⁰rheumatology, CHU Angers, Angers, France, ¹¹Rheumatology, Brest University Medical School Hospital, Brest, France
Background/Purpose: Whipple's disease should be considered in patients with recurrent episodes of seronegative arthritis in the large limb, various symptoms (fever, uveitis,...) or biological abnormalities…
Abstract Number: 1457 • 2017 ACR/ARHP Annual Meeting
Perioperative Management of Methotrexate and Tumor Necrosis Factor Inhibitor Combination Therapy in Rheumatoid Arthritis Patients
Hsin-Hsuan Juo^1,2 and Bernard Ng^1,3, ¹rheumatology, University of Washington, seattle, WA, ²rheumatology, VA Puget Sound Health Care System, seattle, WA, ³Rheumatology, VA Puget Sound Health Care System, seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher frequency of requiring surgical procedures and worse surgical outcome. However, literature regarding post-surgical infectious outcome associated with…
Abstract Number: 1587 • 2017 ACR/ARHP Annual Meeting
Mycobacterial Infection in Systemic Lupus Erythematosus: Clinical Significance and Associated Factors. Data from the Registry of Patients with SLE of the Spanish Society of Rheumatology (RELESSER)
Ana Lois-Iglesias¹, Víctor del Campo-Pérez², Iñigo Rúa-Figueroa³, Coral Mouriño-Rodriguez⁴, Francisco Javier López Longo⁵, María Galindo⁶, Jaime Calvo-Alen⁷, Jesús Ibañez Ruán⁸, Alejandro Olivé⁹, Rafael-Benito Melero González⁴, Antonio Fernandez-Nebro¹⁰, José Antonio Bernal¹¹, Celia Erausquin¹², Eva Tomero¹³, Maria Loreto Horcada¹⁴, Esther Uriarte¹⁵, Mercedes Freire¹⁶, Carlos Alberto Montilla-Morales¹⁷, Ana Sánchez Atrio¹⁸, Alina Boteanu¹⁹, Elvira Diez Alvarez²⁰, Javier Narváez²¹, Víctor Martínez Taboada²², Lucía Silva Fernández²³, Esther Ruiz Lucea²⁴, Jose Luis Andreu²⁵, José Hernández Beiraín²⁶, Marian Gantes²⁷, Blanca Hernández-Cruz²⁸, Jose Javier Perez Venegas²⁹, Ángela Pecondón Español³⁰, Nuria Lozano-Rivas³¹, Monica Ibanez Barcelo³², Gema Bonilla³³, Vicente Torrente³⁴, Ivan Castellví³⁵, Juan José Alegre³⁶, Mireia Moreno³⁷, José Luis Marenco de la Fuente³⁸, Cesar Magro-Checa³⁹, Tomás Vázquez Rodríguez⁴⁰, Victor Quevedo⁴¹, Patricia Richi⁴², Maria Teresa Oton Sanchez⁴³ and JM Pego-Reigosa⁴⁴, ¹Rheumatology, University Hospital A Coruña, A Coruña, Spain, ²Preventive Medicine and Epidemiology, EOXI Vigo, Vigo, Spain, ³Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁴Rheumatology, EOXI Vigo, Vigo, Spain, ⁵Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ⁶Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ⁸POVISA, Rheumatology, Vigo, Spain, ⁹Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁰Rheumatology, Regional Universitary Hospital of Málaga, Malaga, Spain, ¹¹Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, ¹²Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain, ¹³Hospital La Princesa. Madrid., Madrid, Spain, ¹⁴Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁵Reumatología, Hospital de Donosti, Donosti, Spain, ¹⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁷Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹⁸University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain, ¹⁹University Hospital Ramón y Cajal, Madrid, Spain, ²⁰Complejo Asistencial Universitario de León. León. Spain, León, Spain, ²¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²²Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ²³Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²⁴Hospital de Basurto, Bilbao, Spain, ²⁵Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²⁷Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ²⁸Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ²⁹Rheumatology, Hospital de Jerez de la Frontera, Jerez de la Frontera, Spain, ³⁰Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ³¹Rheumatology, Hospital Virgen de la Arrixaca, murcia, Spain, ³²H. Son Llatzer, Palma de Mallorca, Spain, ³³Hospital Universitario La Paz, Madrid, Spain, ³⁴Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain, ³⁵Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ³⁶Sección de Reumatología Hospital Universitario Dr Peset Valencia, Valencia, Spain, ³⁷Rheumatology, Hospital Universitari Parc Taulí, Sabadell, Spain, ³⁸Rheumatology, Hospital de Valme, Seville, Spain, ³⁹Department of Rheumatology, Leiden University Medical Center, Leiden, Spain, ⁴⁰Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ⁴¹Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴²Hospital Infanta Sofía, Madrid, Spain, ⁴³Rheumatology Department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ⁴⁴Rheumatology Section, Hospital de Meixoeiro, Pontevedra, Spain, Vigo, Spain
Background/Purpose: The aim of this work is to study the prevalence of mycobacterial infection (M.I.), the associated factors and their clinical significance in patients included…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].